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Introduction: Diabetes mellitus is a well-defined risk
factor for peripheral artery disease (PAD), but protects
against the development and growth of abdominal
aortic aneurysm (AAA). Diabetes mellitus is associated
with arterial stiffening and peripheral arterial media
sclerosis. Advanced glycation end-products (AGEs) are
increased in diabetes mellitus and cardiovascular
disease. AGEs are known to form cross-links between
proteins and are associated with arterial stiffness.
Whether AGEs contribute to the protective effects of
diabetes mellitus in AAA is unknown. Therefore, the
ARTERY (Advanced glycation end-pRoducts in patients
with peripheral arTery disEase and abdominal aoRtic
aneurYsm) study is designed to evaluate the role of
AGEs in the diverging effects of diabetes mellitus on
AAA and PAD.
Methods and analysis: This cross-sectional
multicentre study will compare the amount, type and
location of AGEs in the arterial wall in a total of 120
patients with AAA or PAD with and without diabetes
mellitus (n=30 per subgroup). Also, local and systemic
vascular parameters, including pulse wave velocity, will
be measured to evaluate the association between
arterial stiffness and AGEs. Finally, AGEs will be
measured in serum, urine, and assessed in skin with
skin autofluorescence using the AGE Reader.
Ethics and dissemination: This study is approved
by the Medical Ethics committees of University Medical
Center Groningen, Martini Hospital and Medisch
Spectrum Twente, the Netherlands. Study results will
be disseminated through peer-reviewed journals and
scientific events.
Trial registration number: trialregister.nl NTR 5363.
BACKGROUND
Diabetes mellitus is a risk factor for
various diseases, including retinopathy,
renal insufﬁciency and atherosclerosis.1
Remarkably, diabetes mellitus is a risk factor
for peripheral artery disease (PAD), but pro-
tects against the development of abdominal
aortic aneurysm (AAA). Evidence for an
inverse association between diabetes mellitus
and AAA was shown in a large case–control
study with veterans (n=73 451) in which an
AAA was detected in 1031 participants.2 This
study demonstrated an OR of 0.54 for the
presence of diabetes mellitus and AAA.2
This inverse association was conﬁrmed by a
meta-analysis consisting of 17 large studies.3
In addition, AAA growth was shown to be
decreased substantially in patients with dia-
betes mellitus (n=49) as compared to those
without diabetes mellitus (n=311) after
36 months of follow-up.4 The explanation
for the diverging effects of diabetes mellitus
Strengths and limitations of this study
▪ Large number of arterial tissue samples (n=120).
▪ Four well-defined subgroups to compare different
research questions: patients with peripheral
artery disease and patients with an abdominal
aortic aneurysm equally divided with and without
diabetes mellitus.
▪ State-of-the-art quantitative measurements of
advanced glycation end-products (AGEs).
▪ Availability of additional biomaterials (skin,
venous tissue, fat tissue, blood and urine) for
in-depth analysis of the distribution of AGEs and
other tissue markers.
▪ Biopsy material may not include specific predi-
lection sites for aneurysm rupture and may not
represent status of vascular tissue in general due
to heterogeneity.
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on occlusive versus dilating arterial disease remains
unclear.
Differences in effects of diabetes mellitus on aorta
versus large peripheral arteries may contribute to these
diverging effects.5 6 AAA is characterised by inﬂammation
of the tunica media with matrix metalloproteinase and
macrophage activation, causing proteolysis and smooth
muscle cell apoptosis.7 8 In contrast, PAD results from
inﬂammation of the tunica intima and increased endo-
thelial permeability, macrophage inﬁltration, retention of
cholesterol and recruitment of smooth muscle cells which
form a ﬁbrous cap.9 Nevertheless, AAA and PAD appear
often simultaneously in patients, possibly due to their
common risk factors. Diabetes-induced changes in arter-
ial pulse wave propagation and reﬂection may be another
factor contributing to the diverging effects of diabetes on
increased occlusive arterial disease in the lower extrem-
ities and relative protection against AAAs. Type 2 diabetes
is associated with increased aortic stiffness, without abnor-
malities in aortic diameter or carotid stiffness.10 Patients
with type 2 diabetes demonstrate a decreased reﬂection
magnitude, which may indicate an increased penetration
of pulsatile energy to distal vascular beds.10
Advanced glycation end-products (AGEs) might also
play a role in these different effects of diabetes mellitus
on vascular tissues. AGEs are formed by non-enzymatic
glycaemic and oxidative stress reactions. Diseases with
increased glycaemic or oxidative stress are associated
with increased AGE levels. Indeed, increased serum and
skin AGEs are found in patients with diabetes mellitus
compared to controls.11–13 Oxidative stress plays a role
in the pathogenesis of AAA and PAD.14 15 In line with
this reasoning, increased serum AGEs and skin AGEs
were found in patients with PAD as compared to con-
trols.16 17 Furthermore, our data show increased skin
AGEs, non-invasively assessed, in 252 patients with AAA
compared to controls (Boersema J et al, unpublished
data, 2017). Two effects of AGEs have been described,
namely formation of cross-links on long-lived proteins
and induction of cellular stress responses by engage-
ment of the receptor for AGEs.18 Cross-linking causes
stiffness, but may also protect against mechanical struc-
ture loss of the affected tissues. The association between
AGEs and arterial stiffness is shown in several studies. In
patients with end-stage renal disease and in type 1 dia-
betes mellitus, skin AGE level was associated with pulse
wave velocity, a measure of arterial stiffness.19 20
Increased arterial stiffness is associated with atheroscler-
otic disease.21 However, in a mouse model, homogenous
stiffening reduced aneurysm growth, whereas segmental
aortic stiffening caused aneurysm growth.22
Therefore, the aim of the ARTERY study (Advanced
glycation end-pRoducts in patients with peripheral
arTery disEase and abdominal aoRtic aneurYsm study)
is to identify the association between the presence of
diabetes mellitus and increased accumulation of AGEs
and arterial stiffening in the vascular wall in patients
with AAA and PAD. If an association would be found, it
would support our hypothesis that increased AGE accu-
mulation may cause homogenous stiffness of the vascu-
lar wall and protect against AAA development and




To compare the amount of AGEs in the vascular wall
between patients with and without diabetes mellitus suf-
fering from:
▸ Abdominal aortic aneurysm.
▸ Peripheral artery disease.
Secondary objectives
Our secondary objectives are:
▸ To compare types and location of the AGEs between
patients with and without diabetes mellitus.
▸ To evaluate the relation between the amount of AGEs
and vascular stiffness within all subgroups.
▸ To correlate AGEs in the vascular wall to serum,
urine and skin AGEs in the whole study group.
Study design
The ARTERY study is designed as a cross-sectional multi-
centre study, performed in three centres in the
Netherlands.
Participants
Patients from at least 18 years on, willing to participate,
are eligible for the study. Patients will be included in
case of the diagnosis of AAA or PAD in whom an indica-
tion for open surgery exists. Patients with concomitant
AAA and PAD will be excluded, as well as patients with
inﬂammatory disorders. Detailed inclusion and exclu-
sion criteria are summarised in table 1. Patients will be
divided into four groups, based on the diagnosis of AAA
or PAD and the presence or absence of diabetes mellitus
(ﬁgure 1). American Diabetes Association guidelines
will be used to deﬁne diabetes mellitus. The diagnosis of
diabetes mellitus will be supposed by a random glucose
≥11.1 mmol/L, HbA1c ≥6.5% or 48 mmol/mol or a
history of diabetes mellitus.1
In total, 120 patients will be included in the ARTERY
study. This number is based on two sample size calcula-
tions. For our primary objective, calculation was based on
a study which compared the content of the speciﬁc AGE
pentosidine in plaques of diabetic and non-diabetic
patients with carotid artery stenosis. In this study, a signiﬁ-
cant difference was found in 7 patients with diabetes mel-
litus (197.0±34.0 pmol/mg collagen) and 20 patients
without diabetes mellitus (111.9±16.2 pmol/mg colla-
gen).23 With a power of 80% and an α of 5%, each group
has to consist of three patients. With four groups in our
study, this would result in at least 12 patients. However,
for our secondary objectives, an additional sample size
calculation was performed. This calculation was based on
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skin AGEs in patients with and without diabetes mellitus.
This study reported a mean skin AGE level of 2.79±0.8
arbitrary units (AU) in 973 patients with diabetes mellitus
and 2.14±0.6 AU in 231 patients without diabetes melli-
tus.13 To show a similar difference between patients with
and without diabetes mellitus of skin AGEs, 25 patients
per group are required. Taking a failure plus dropout
rate of 20% into account together with the possibility of
subgroup analysis, we should include 30 patients per sub-
group and a total of 120 patients.
Recruitment
The patients will be recruited from the outpatient clinic
of vascular surgery located in one of the three following
Dutch hospitals: University Medical Center Groningen
(UMCG), Martini Hospital Groningen and Medisch
Spectrum Twente (MST).
Patients will be informed about the study by their
treating vascular surgeon. Detailed written and oral
information will be given by the investigator or research
coordinator.
Study procedures
After signing the informed consent form, patients are
asked to ﬁll in a questionnaire and have an appointment
in the vascular laboratory. Blood will be drawn and
24-hour urine will be collected before surgery. Several
biopsies will be obtained during surgery, depending on
the type of surgery, and of which more details are shown
below. Collected tissue biopsies will be stored until analysis.
Blood and urine sampling
Blood will be sampled for routine analysis and stored to
determine AGEs. For direct analysis, blood will be drawn
in an EDTA tube, lithium heparin tube and a sodium
ﬂuoride tube. Citrate plasma, EDTA plasma and serum
will be stored at −80°C. For the analysis of AGEs, EDTA
tubes will be used for blood collection, which will be
transported on ice, centrifuged on 4°C and stored at
−80°C until batch analysis.
Patients will be asked to collect urine for 24 hours and
to keep the container cool until the urine is returned to
the laboratory. The urine will be centrifuged, routine
Table 1 Inclusion and exclusion criteria
Inclusion criteria Exclusion criteria
AAA ▸ An aneurysm of the abdominal aorta ≥50 mm for women,
≥55 mm for men or a growth rate of ≥10 mm per year as
demonstrated on duplex ultrasound, computed tomographic
angiography or magnetic resonance angiography.
▸ And scheduled for an open repair of the aneurysm.
▸ Patients with signs of an inflammatory or mycotic
aneurysm on computed tomographic angiography.
▸ Patients with an AAA as a result of an aortic
dissection.
▸ Patients with an AAA and PAD, defined as an
ankle-brachial index of <0.80 or a toe pressure of
<50 mm Hg.
▸ Patients with Ehlers-Danlos syndrome or Marfan
syndrome.
PAD ▸ Proven PAD with an ankle-brachial index of <0.80, or a toe
pressure of <50 mm Hg, or confirmation of PAD on duplex
ultrasound, computed tomographic angiography, magnetic
resonance angiography or angiography.
▸ And scheduled for open bypass surgery or open
endarterectomy of the lower extremity arteries.
▸ PAD caused by local radiation therapy.
▸ Patients with PAD and an abdominal aorta of
≥30 mm.
AAA, abdominal aortic aneurysm; PAD, peripheral artery disease.
Figure 1 Patient groups.
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analysis will be performed and samples will be stored
at −80°C.
Biopsy
During surgery, full-thickness biopsies from the arterial
wall will be taken at predeﬁned locations. These biopsies
will be marked with sutures to assure cranio-caudal
directions.
▸ In case of an open aneurysm repair, a biopsy will be
obtained 5 cm below the lowest renal artery on the
left ventral side with a size of 3 (length)×1
(width) cm.
▸ In case of bypass surgery for PAD, a biopsy will be
obtained from the proximal anastomosis in the groin
of 1 (length)×0.5 (width) cm.
▸ In case of an endarterectomy for PAD, usually the
common femoral artery, a biopsy will be obtained
from the proximal part of the artery with a size of 1
(length)×0.5 (width) cm.
In addition, skin tissue, venous tissue and fat tissue
will be obtained and stored as described below. Skin
tissue will be obtained from the incision with a size of 1
(length)×0.5 (width)×1 (depth) cm. Venous tissue is
only available in case of an autologous venous bypass. In
that case, a circular segment from the venous graft will
be obtained at the level of the distal anastomosis with a
size of 0.25–0.50 cm. Peri-aortic adipose tissue will be
obtained during open aneurysm repair and perivascular
adipose tissue will be obtained from the groin when
available during bypass surgery or endarterectomy for
PAD.
Storage
After surgery, biopsy material of the arterial tissue will
be divided into three equal parts. The ﬁrst two parts,
together with skin, venous and adipose tissue, will be
snap frozen and stored at −80°C. The third part,
marked with a suture on the most distal part of the
biopsy, will be stored in formaldehyde for 24–72 hours.
Afterwards, tissue will be dehydrated with ethanol and
embedded in parafﬁn. Materials of MST will be ﬁxed
with formaldehyde, stored in 96% ethanol and trans-
ported to the UMCG per batch of 10 samples where
these tissues will be embedded in parafﬁn. Additional
biopsy material, which will not be used for primary or
secondary research questions, will be stored for future
research. Information about the use of additional tissue
for future research is included in the patient informa-
tion and in the informed consent form.
Outcome measures
Table 2 presents an overview of the outcome measures
and measurement methods, which will be described in
detail in the following paragraphs.
Demographics
The patients’ characteristics such as date of birth, sex,
cardiovascular risk factors, cardiovascular disease, cardio-
vascular family history, duration of diabetes mellitus, gly-
caemic control and drug use will be assessed by
evaluating medical records and will be conﬁrmed or
complemented by a questionnaire consisting of 25
questions.
Table 2 Measures and methods
Domain Outcome measure Methods/equipment











Routine blood analysis, including random glucose, HbA1c,
creatinine, total cholesterol, LDL, HDL, triglycerides, ALAT,
ASAT, gamma-GT, LDH, TSH, T4 and hsCRP.
EDTA, li-heparine tube, NaF tube.
Weight Seca 877 scale
AGEs in arterial wall Quantitative measurement High-performance liquid chromatography
Types and localisation Immunohistochemistry
AGEs in fluids Serum AGEs High-performance liquid chromatography
Urine AGEs High-performance liquid chromatography
Skin AGEs Skin autofluorescence AGE Reader
Vascular parameters Blood pressure Microlife WatchBP Office
Ankle-brachial index Vicorder
Diameter aorta Siemens Acuson S2000
Intima-media thickness Esaote MyLabOne
Pulse wave velocity Sphygmocor EM3
AGEs, advanced glycation end-products; ALAT, alanine aminotransferase; ASAT, aspartate aminotransferase; GT, glutamyltransferase;
HDL, high-density lipoprotein; hsCRP, high sensitivity C-reactive protein; LDH, lactate dehydrogenase; LDL, low-density lipoprotein; TSH,
thyroid-stimulating hormone.
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Weight, length, waist and hip diameter will be recorded
during visit at the vascular laboratory. Routine blood and
urine analysis will be performed to evaluate the presence
of diabetes mellitus and to determine several cardiovas-
cular risk factors, including renal function.
AGEs in arterial wall
Analysis of AGEs in the arterial wall, serum and urine
will be performed by the laboratory for Metabolism and
Vascular Medicine, Maastricht University Medical
Center, the Netherlands. Protein-bound carboxylmethyl-
lysine (CML), Nε-(carboxyethyl)lysine (CEL) and
5-hydro-5-methylimidazolone (MG-H1) will be measured
in the ﬁrst part of the arterial biopsy material with
ultra-performance liquid chromatography tandem
mass spectrometry (UPLC–MS/MS), as described
previously.24
To localise different types of AGEs, 4 mm slices will be
made from the parafﬁn-embedded arterial tissue.
Consecutive slices will be stained with several antibodies,
including polyclonal anti-AGE antibody (Abcam,
ab23722), monoclonal anti-AGE antibody for lysine deri-
vatives (Biorbyt, orb27490) and monoclonal anti-
pentosidine (Biorbyt, orb27502).
AGEs in fluids
Speciﬁc protein-bound plasma and urine AGEs, CML,
CEL and MG-H1, will be measured with UPLC–MS/MS,
as described previously.25 Protein-bound plasma and
urine pentosidine will be measured using high-
performance liquid chromatography, as described
previously.26
Skin AGEs
AGEs in the skin will be assessed non-invasively with the
AGE Reader (DiagnOptics Technologies BV, Groningen,
the Netherlands). This method uses ultraviolet light to
excite speciﬁc AGEs. Reﬂection and emission light are
detected and converted into a skin autoﬂuorescence
(SAF) level expressed in AUs. Detailed information
about this method is described elsewhere.27 Both inner
forearms will be scanned three times. Patients will be
asked not to use sun blockers, skin tanners or skin
creams 2 weeks before the measurement, since these
creams inﬂuence the SAF measurement.28
Vascular parameters
Several vascular parameters will be obtained for the
ARTERY study. These parameters include blood pres-
sures, toe pressures and duplex ultrasound of the aorta.
In addition, carotid artery intima-media thickness
and carotid-femoral pulse wave velocity will be measured
in the vascular laboratory of the UMCG only.
Measurements will be performed by trained vascular
technicians.
Brachial artery blood pressures will be measured three
times on both arms in sitting position after 10 min of
rest.
For the ankle-brachial index measurement, patients
should be in supine position. For the ankle-brachial
index, the systolic pressure will be measured of the bra-
chial artery, and the posterior tibial artery and the dor-
salis pedis artery bilaterally. This will be measured during
cuff release using a Doppler probe. Toe-brachial index
will be measured using toe photo-electric plethysmogra-
phy during gradual pressure release of a cuff placed at
the base of the ﬁrst toe, the toe pressure being deﬁned
by reappearance of the plethysmographic signal.
Screening to exclude concomitant AAA and PAD will
be performed with duplex ultrasound in supine pos-
ition. An AAA will only be reassessed in case the last
imaging procedure was more than 2 months ago.
Carotid intima-media thickness will be measured as a
marker of generalised atherosclerotic burden. The far
wall of the left and right common carotid artery will be
measured with the MyLabOne (Esaote Europe B.V.,
Maastricht, the Netherlands). Three measurements will
be performed with an average of six heart beats of the
wall segment of 10 mm before the transition to the
carotid bulb.
For the measurement of the carotid-femoral pulse
wave velocity, patients are asked not to drink coffee or
alcohol and not to smoke 3 hours before the measure-
ment. Patients are allowed to have a light meal. Arterial
waveforms will be obtained from the carotid and
femoral artery and the time delay will be measured
between the feet of the two waveforms. The distance
covered by the waves will be established as 80% of the
distance between the two recording sites. Pulse wave vel-
ocity will be calculated as distance/time delay in m/s
with the use of the Sphygmocor EM3 (AtCor Medical
Pty, West Ryde, Australia).
Data handling and statistical analysis
Informed consent forms will be collected and stored at
the UMCG. Biomaterials from patients will be coded. All
generated data will be stored and coded in an electronic
Case Report File with the software OpenClinica. Data
will be exported to the SPSS software (IBM Corp.,
Armonk, New York, USA) for statistical analysis.
Described data will be shown as mean with SD for
normal distributed variables, mean with IQR for
skewed data and number with percentages for categor-
ical data. Difference between groups will be tested
with the independent Student’s t-test or non-
parametric tests for skewed data. For categorical vari-
ables, χ2 test will be performed. After comparing dif-
ferences with a univariate analysis, multivariable
analyses will be performed to adjust for important
confounders of AGEs. A value of p<0.05 will be consid-
ered signiﬁcant.
Ethics consideration
All investigators performed and passed the examination
of the Dutch Basic course on Regulations and
Organisation for clinical investigators.
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DISCUSSION
The ARTERY study is designed to deﬁne the possible
role of AGEs in the protection against AAA formation in
diabetes mellitus. The protocol for this cross-sectional
multicentre study addresses this issue by combining local
and systemic AGE assessments with vascular functional
and imaging methods.
Several research groups have evaluated the localisation
and content of AGEs in human tissue before. Most
studies have been performed assessing skin AGE levels.29
Furthermore, Hofman et al described the measurement
of AGEs in right atrial appendages and vein graft mater-
ial from patients with coronary artery disease.30 31
However, to the best of our knowledge, this is the ﬁrst
study that will compare AGE accumulation in human
vascular tissue and will investigate the effects of diabetes
mellitus on AGE accumulation and distribution in differ-
ent vascular diseases. Furthermore, the current study has
been designed to provide answers on several additional
research questions, including the association between
tissue AGEs and vascular stiffness. In addition, this study
will show the association between skin AGEs measured
non-invasively and AGEs measured in vascular tissue,
urine and blood.
The AGE Reader uses ﬂuorescence for assessing skin
AGEs. SAF is strongly associated with AGEs from skin
biopsies.27 Several studies have shown that SAF, mea-
sured with the use of the AGE Reader, is related to arter-
ial parameters such as pulse wave velocity and
intima-media thickness, and predicts cardiovascular
events.19 32–35 However, the correlation between AGEs
measured in the arterial wall compared to SAF is
unknown. It is likely that there is a correlation between
both, since Hofmann et al30 showed that skin AGE levels
were strongly correlated to AGEs in cardiac tissue from
patients with coronary artery disease. A strong associ-
ation between AGEs of the arterial wall and AGEs mea-
sured with SAF would underscore the role of the AGE
Reader as an easy and non-invasive technique as a
marker of vascular tissue accumulation.
Although we designed our study carefully, there are
some limitations. We do not exclude patients suffering
from renal insufﬁciency. These patients also have
increased AGE accumulation.36 We have chosen not to
exclude these patients, since patients with vascular
disease frequently have renal insufﬁciency. Exclusion of
patients with concurrent renal failure and vascular
disease would result in a selection bias. Therefore, we
have decided to increase our sample size to allow sub-
group analysis. In addition, renal function will be a vari-
able which will be included into multivariate analyses. In
addition, biopsy material obtained at the location of
disease may not be representative for vascular tissue in
general. We standardise the biopsies procedure to min-
imise location-speciﬁc differences. However, it is technic-
ally and ethically not possible to obtain additional
biopsies from different vascular sites to determine
whether AGEs are distributed equally.
In conclusion, the ARTERY study will investigate the
diverging effects of diabetes mellitus on AAA and PAD
and the role of AGEs as a possible explanatory factor.
The study will be conducted in a multicentre setting.
Primary objective is to analyse AGEs in the arterial wall.
As secondary objectives, AGEs of the arterial wall will be
compared to AGE measurements in blood, urine and
skin, and with vascular wall parameters.
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